Table 1.
List of dual Pi3K/mTOR inhibitors sorted by their official name, if assigned, or by their common/alternative name.
| Official Name | Common/Alternative Name | Company/Developer | Ability to Cross the BBB | Clinical Stage | Orphan Drug Status | Development Status * |
|---|---|---|---|---|---|---|
| Apitolisib | GDC-0980, RG7422 | Genentech; Piramed | No/low | Phase I/II | - | Discontinued * |
| Bimiralisib | PQR309 | Piqur Therapeutics | yes | Phase I/II | DLBCL | On-going trials |
| Dactolisib | BEZ235, NVP-BEZ235, RTB-101, NVP-BEZ235-NX | Novartis; resTORbio | n.a. | |||
| Gedatolisib | PF-05212384/PKI-587, 1197160-78-3 | Wyeth; Pfizer | n.a. | Phase I/II/III | - | On-going trials |
| Omipalisib | GSK2126458, GSK458, GSK-212 | GlaxoSmithKline | yes | Phase I | - | No on-ongoing trials |
| Panulisib | P7170, S9WA04F921 | Piramal Healthcare | n.a. | Phase I | - | No on-going trials |
| Samotolisib | LY3023414, GTPL8918 | Eli Lilly and Company | n.a. | Phase I/II | - | Discontinued * |
| Voxtalisib | XL765, SAR245409 | EMD Serono; Exelixis; Sanofi | yes | Phase I/II | - | Discontinued * |
| - | BGT226, NVP-BGT226 | Novartis | n.a. | Phase I/II | - | Discontinued * |
| - | DS7423, 70895382 | Daiichi Sankyo | yes | Phase I | - | Discontinued * |
| - | GDC-0084, RG 7666 | Genentech; Kazia Therapeutics | yes | Phase I/II/III | glioblastoma multiforme | On-going trials |
| - | GNE-477 | Genentech | n.a. | - | - | No on-going trials |
| - | PF-04691502 | Pfizer | n.a. | Phase I/II | - | Discontinued * |
| - | PF-04979064 | Pfizer | n.a. | - | - | No on-going trials |
| - | PI-103, 9884685 | Merck | yes | - | - | No on-going trials |
| - | PKI-179 | Wyeth; Pfizer | n.a. | - | - | Discontinued * |
| - | PKI-402, 44187953 | Wyeth | n.a. | - | - | No on-going trials |
| - | PQR530 | Piqur Therapeutics | yes | - | - | No on-going trials |
| - | PWT33597, VDC-597 | Pathway Therapeutics; VetDC | n.a. | Phase I | - | No on-going trials |
| - | SF-1126 | Semafore; SignalRx Pharmaceuticals | n.a. | Phase I | CLL | Status unknown |
| - | SN32976, 1246202-11-8 | The University of Auckland | n.a. | - | - | Status unknown |
| - | VS-5584, SB2343 | S*BIO; Verastem | n.a. | Phase I | Mesothelioma | Discontinued * |
n.a., data not available; *, based on http://adisinsight.springer.com/ and/or https://clinicaltrials.gov accessed in December 2019. BBB, blood brain barrier; DLBCL, diffuse large B cell lymphoma; CLL, chronic lymphocytic leukemia.